Sector ratings Gilead Sciences, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 10/12/2025 GMT			5-day change	1st Jan Change
121.34 ^USD	+1.66%		-2.93%	+31.36%

12-10	This Is Decision Day
12-10	Wells Fargo Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
GILEAD SCIENCES, INC.	151B	-	AAA	-	-	-	-	-
ELI LILLY AND COMPANY	890B	-	A	-	-	-	-	-
JOHNSON & JOHNSON	498B	-	BBB	-	-	-	-	-
ABBVIE INC.	398B	-	AA	-	-	-	-	-
ROCHE HOLDING AG	343B	-	AA	-	-	-	-	-
ASTRAZENECA PLC	279B	-	A	-	-	-	-	-
NOVARTIS AG	252B	-	AAA	-	-	-	-	-
MERCK & CO., INC.	242B	-	A	-	-	-	-	-
NOVO NORDISK A/S	214B	-	A	-	-	-	-	-
AMGEN INC.	170B	-	A	-	-	-	-	-
PFIZER INC.	147B	-	BBB	-	-	-	-	-
SANOFI	117B	-	A	-	-	-	-	-
VERTEX PHARMACEUTICALS INCORPORATED	113B	-	AA	-	-	-	-	-
BRISTOL-MYERS SQUIBB COMPANY	104B	-	A	-	-	-	-	-
GSK PLC	96.53B	-	AA	-	-	-	-	-
CHUGAI PHARMACEUTICAL CO., LTD.	85.78B	-	AA	-	-	-	-	-
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	59.61B	-	AA	-	-	-	-	-
ALNYLAM PHARMACEUTICALS, INC.	53.43B	-	AA	-	-	-	-	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	45.29B	-	AA	-	-	-	-	-
Average	216.07B		AA
Weighted average by Cap.			AA